Existing Azumio investors include Founders Fund, Accel Partners, and Felicis Ventures. Although Azumio declined to comment on the funding, the filing suggest five investors participated in this round.
Azumio has developed 24 apps including Instant Heart Rate, which measures a user's heart rate by leveraging a smartphone's camera and flash, Glucose Buddy, which helps users track their glucose intake, and Sleep Time, an alarm clock app that also measures a user's sleep cycle.
Last year, the company also launched Argus, which aggregates readings from many of Azumio’s other apps as well as including built-in tracking for food, sleep, and activity. Unlike most of Azumio’s apps, which are available for Apple and Android, Argus is currently available on iPhone only.
At the time, CTO and cofounder Peter Kuhar told MobiHealthNews they would gradually phase out many of the other apps in favor of having Argus as a comprehensive offering.
"It’s not just another app," he said, "it’s a whole service, a smart engine we’re building in the background. In the future, it’ll be the only health app you need.”
In August 2013, Azumio CEO Bojan Bostjancic told MobiHealthNews Azumio’s apps have a combined 45 million downloads. In September it became one of the first health apps for Samsung's Galaxy Gear smartwatch.
In early 2014, the Azumio was announced as a launch partner for mobile engagement platform Welltok's new program, called CaféWell Connect.
A few months later, at SXSW, Azumio’s Jennifer Grenz discusssed the the liabilities of measuring people’s health. She pointed out that her company’s apps “can track everything for your personal well-being, but we don’t give you an actual diagnostic recommendation,” meaning, the apps are outside the FDA medical device clearance process because they are not claiming to be diagnostic. Grenz discussed what she called “horror stories” about Azumio customers who used their apps to go to the emergency room just before they had a heart attack.